» Articles » PMID: 35056959

Alkylmorpholines: Potent Dermal and Transdermal Skin Permeation Enhancers

Overview
Journal Pharmaceutics
Publisher MDPI
Date 2022 Jan 21
PMID 35056959
Authors
Affiliations
Soon will be listed here.
Abstract

Transdermal drug delivery is an attractive non-invasive method offering numerous advantages over the conventional routes of administration. The main obstacle to drug transport is, however, the powerful skin barrier that needs to be modulated, for example, by transdermal permeation enhancers. Unfortunately, there are still only a few enhancers showing optimum properties including low toxicity and reversibility of enhancing effects. For this reason, we investigated a series of new -alkylmorpholines with various side chains as potential enhancers in an in vitro permeation study, using three model permeants (theophylline, indomethacin, diclofenac). Moreover, electrical impedance, transepidermal water loss, cellular toxicity and infrared spectroscopy measurements were applied to assess the effect of enhancers on skin integrity, reversibility, toxicity and enhancers' mode of action, respectively. Our results showed a bell-shaped relationship between the enhancing activity and the hydrocarbon chain length of the -alkylmorpholines, with the most efficient derivatives having 10-14 carbons for both transdermal and dermal delivery. These structures were even more potent than the unsaturated oleyl derivative. The best results were obtained for indomethacin, where particularly the C10-14 derivatives showed significantly stronger effects than the traditional enhancer Azone. Further experiments revealed reversibility in the enhancing effect, acceptable toxicity and a mode of action based predominantly on interactions with lipids.

Citing Articles

Liposomal Copermeation Assay Reveals Unexpected Membrane Interactions of Commonly Prescribed Drugs.

Odehnalova K, Balouch M, Storchmannova K, Petrova E, Konefal M, Zadrazil A Mol Pharm. 2024; 21(6):2673-2683.

PMID: 38682796 PMC: 11151206. DOI: 10.1021/acs.molpharmaceut.3c00766.


Natural Ingredients of Transdermal Drug Delivery Systems as Permeation Enhancers of Active Substances through the .

Schafer N, Balwierz R, Biernat P, Ochedzan-Siodlak W, Lipok J Mol Pharm. 2023; 20(7):3278-3297.

PMID: 37279070 PMC: 10324402. DOI: 10.1021/acs.molpharmaceut.3c00126.


The Contest of Nanoparticles: Searching for the Most Effective Topical Delivery of Corticosteroids.

Kalvodova A, Dvorakova K, Petrova E, Michniak-Kohn B, Zbytovska J Pharmaceutics. 2023; 15(2).

PMID: 36839836 PMC: 9962773. DOI: 10.3390/pharmaceutics15020513.

References
1.
curikova B, Prochazkova K, Filkova B, Diblikova P, Svoboda J, Kovacik A . Simplified stratum corneum model membranes for studying the effects of permeation enhancers. Int J Pharm. 2017; 534(1-2):287-296. DOI: 10.1016/j.ijpharm.2017.10.038. View

2.
Vavrova K, Hrabalek A, Dolezal P, Samalova L, Palat K, Zbytovska J . Synthetic ceramide analogues as skin permeation enhancers: structure-activity relationships. Bioorg Med Chem. 2003; 11(24):5381-90. DOI: 10.1016/j.bmc.2003.09.034. View

3.
Vovesna A, Zhigunov A, Balouch M, Zbytovska J . Ceramide liposomes for skin barrier recovery: A novel formulation based on natural skin lipids. Int J Pharm. 2021; 596:120264. DOI: 10.1016/j.ijpharm.2021.120264. View

4.
Netzlaff F, Kostka K, Lehr C, Schaefer U . TEWL measurements as a routine method for evaluating the integrity of epidermis sheets in static Franz type diffusion cells in vitro. Limitations shown by transport data testing. Eur J Pharm Biopharm. 2005; 63(1):44-50. DOI: 10.1016/j.ejpb.2005.10.009. View

5.
Khandavilli S, Panchagnula R . Dermal drug delivery: Revisited. Drug Discov Ther. 2012; 2(2):64-73. View